Current Issues in Molecular Biology,
Год журнала:
2023,
Номер
45(10), С. 8053 - 8070
Опубликована: Окт. 1, 2023
Since
the
discovery
of
dendritic
cells
(DCs)
in
1973
by
Ralph
Steinman,
a
tremendous
amount
knowledge
regarding
these
innate
immunity
has
been
accumulating.
Their
role
regulating
both
and
adaptive
immune
processes
is
gradually
being
uncovered.
DCs
are
proficient
antigen-presenting
capable
activating
naive
T-lymphocytes
to
initiate
generate
effective
anti-tumor
responses.
Although
DC-based
immunotherapy
not
yielded
significant
results,
substantial
number
ongoing
clinical
trials
underscores
relevance
DC
vaccines,
particularly
as
adjunctive
therapy
or
combination
with
other
treatment
options.
This
review
presents
an
overview
current
human
DCs,
their
classification,
functions
distinct
populations.
The
stepwise
process
developing
therapeutic
vaccines
treat
oncological
diseases
discussed,
along
speculation
on
potential
combined
approaches
modern
immunotherapy.
EBioMedicine,
Год журнала:
2024,
Номер
100, С. 104963 - 104963
Опубликована: Янв. 5, 2024
Glioblastoma
(GBM)
is
one
of
the
most
lethal
central
nervous
systems
(CNS)
tumours
in
adults.
As
supplements
to
standard
care
(SOC),
various
immunotherapies
improve
therapeutic
effect
other
cancers.
Among
them,
tumour
vaccines
can
serve
as
complementary
monotherapy
or
boost
clinical
efficacy
with
immunotherapies,
such
immune
checkpoint
blockade
(ICB)
and
chimeric
antigen
receptor
T
cells
(CAR-T)
therapy.
Previous
studies
GBM
have
suggested
that
few
neoantigens
could
be
targeted
due
low
mutation
burden,
single-peptide
vaccination
had
limited
control
monotherapy.
Combining
diverse
antigens,
including
neoantigens,
tumour-associated
antigens
(TAAs),
pathogen-derived
optimizing
vaccine
design
strategy
may
help
improvement.
In
this
review,
we
discussed
current
platforms,
evaluated
potential
antigenic
targets,
challenges,
perspective
opportunities
for
Cellular and Molecular Immunology,
Год журнала:
2024,
Номер
21(12), С. 1354 - 1375
Опубликована: Окт. 15, 2024
Glioblastoma
(GBM)
is
an
aggressive
and
lethal
type
of
brain
tumor
in
human
adults.
The
standard
care
offers
minimal
clinical
benefit,
most
GBM
patients
experience
recurrence
after
treatment.
In
recent
years,
significant
advancements
have
been
made
the
development
novel
immunotherapies
or
other
therapeutic
strategies
that
can
overcome
immunotherapy
resistance
many
advanced
cancers.
However,
benefit
immune-based
treatments
limited
because
unique
immune
profiles,
cell
heterogeneity,
immunosuppressive
microenvironment.
this
review,
we
present
a
detailed
overview
current
immunotherapeutic
discuss
challenges
potential
molecular
mechanisms
underlying
GBM.
Furthermore,
provide
in-depth
discussion
regarding
GBM,
which
will
likely
require
combination
therapies.
The
circadian
clock
is
an
internal
timekeeper
system
that
regulates
biological
processes
through
a
central
and
peripheral
clocks
controlling
various
genes.
Basic
helix-loop-helix
ARNT-like
1
(BMAL1),
also
known
as
aryl
hydrocarbon
receptor
nuclear
translocator-like
protein
(ARNTL1),
key
component
of
the
clock.
deletion
BMAL1
alone
can
abolish
rhythms
human
body.
plays
critical
role
in
immune
cell
function.
Dysregulation
linked
to
immune-related
diseases
such
autoimmune
diseases,
infectious
cancer,
vice
versa.
This
review
highlights
significant
governing
cells,
including
their
development,
differentiation,
migration,
homing,
metabolism,
effector
functions.
study
explores
how
dysregulation
have
far-reaching
implications
potentially
contribute
onset
sepsis,
trauma.
Furthermore,
this
discusses
treatments
for
target
disorders.
Understanding
impact
on
function
provide
insights
into
pathogenesis
help
development
more
effective
treatment
strategies.
Targeting
has
been
demonstrated
achieve
good
efficacy
indicating
its
promising
potential
targetable
therapeutic
these
diseases.
Life,
Год журнала:
2025,
Номер
15(2), С. 276 - 276
Опубликована: Фев. 11, 2025
Recent
advances
in
virology,
particularly
the
study
of
HIV-1,
have
significantly
progressed
pursuit
a
definitive
cure
for
disease.
Emerging
therapeutic
strategies
encompass
innovative
gene-editing
technologies,
immune-modulatory
interventions,
and
next-generation
antiretroviral
agents.
Efforts
to
eliminate
or
control
viral
reservoirs
also
gained
momentum,
with
aim
achieving
durable
remission
without
continuous
requirement
therapy.
Despite
these
promising
developments,
critical
challenges
persist
bridging
gap
between
laboratory
findings
clinical
implementation.
This
review
provides
comprehensive
analysis
recent
breakthroughs,
ongoing
trials,
barriers
that
must
be
addressed
translate
advancements
into
effective
treatments,
emphasizing
multifaceted
approaches
being
pursued
achieve
curative
solution
HIV-1
infection.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,
Год журнала:
2024,
Номер
16(4)
Опубликована: Июль 1, 2024
Abstract
mRNA
therapeutics
have
shown
great
potential
for
a
broad
spectrum
of
disease
treatment.
However,
the
challenges
mRNA's
inherent
instability
and
difficulty
in
cellular
entry
hindered
its
progress
biomedical
field.
To
address
barriers
deliver
to
cells
interest,
various
delivery
systems
are
designed.
Among
these,
lipid
nanoparticles
(LNPs)
stand
out
as
most
extensively
used
systems,
particularly
following
clinical
approvals
corona
virus
2019
(COVID‐19)
vaccines.
LNPs
comprised
ionizable
cationic
lipids,
phospholipids,
cholesterol,
polyethylene
glycol
derived
lipids
(PEG‐lipids).
In
this
review,
we
primarily
summarize
recent
advancements
LNP
technology,
focusing
on
structures
four
constituents
their
applications.
We
delve
into
structure–activity
relationships
while
also
exploring
future
prospects
developing
more
efficacious
systems.
This
article
is
categorized
under:
Therapeutic
Approaches
Drug
Discovery
>
Emerging
Technologies
Biology‐Inspired
Nanomaterials
Lipid‐Based
Structures
Nanotechnology
Biology
Nanoscale
Systems
Abstract
mRNA
therapeutics
have
significantly
evolved
within
the
life
sciences,
particularly
in
applications
such
as
vaccines,
tumor
immunotherapy,
protein
replacement,
gene
editing,
and
monoclonal
antibody
therapy.
To
fully
realize
potential
of
drugs
mitigate
adverse
effects,
substantial
vector
materials
been
developed
for
delivery
these
pharmaceutical
agents.
Lipid
nanoparticles
(LNPs)
represent
most
clinically
advanced
carriers,
recognized
by
U.S.
Food
Drug
Administration
approved
vaccines
numerous
clinical
trials.
Diverse
therapeutic
necessitate
tailored
design
LNPs.
Herein,
we
outline
principles
LNP
delivery,
focusing
specifically
on
their
effectiveness,
targeting
capabilities,
safety
profiles,
nanoparticle
stability.
Additionally,
present
latest
advancements
mRNA‐LNP
technology.
This
review
aims
to
elucidate
benefits
systems
therapeutics,
providing
insights
into
breakthroughs
innovative
ideas
further
enhancing
advantages.
These
summaries
are
dedicated
promoting
broader
LNP‐mRNA
drugs,
aiming
advance
treatment
serious
diseases
an
effective
safe
manner.
Journal of Translational Medicine,
Год журнала:
2023,
Номер
21(1)
Опубликована: Ноя. 18, 2023
Abstract
Advancing
personalized
medicine
in
brain
cancer
relies
on
innovative
strategies,
with
mRNA
vaccines
emerging
as
a
promising
avenue.
While
the
initial
use
of
was
oncology,
their
stunning
success
COVID-19
resulted
widespread
attention,
both
positive
and
negative.
Regardless
politically
biased
opinions,
which
relate
more
to
antigenic
source
than
form
delivery,
we
feel
it
is
important
objectively
review
this
modality
relates
cancer.
This
class
trigger
robust
immune
responses
through
MHC-I
MHC-II
pathways,
prophylactic
therapeutic
settings.
The
platform
offers
advantages
rapid
development,
high
potency,
cost-effectiveness,
safety.
provides
an
overview
vaccine
delivery
technologies,
tumor
antigen
identification,
combination
therapies,
recent
outcomes,
particular
focus
Combinatorial
approaches
are
vital
maximizing
efficacy,
ongoing
clinical
trials
exploring
combinations
adjuvants
checkpoint
inhibitors
even
adoptive
cell
therapy.
Efficient
neoantigen
preclinical
studies,
trial
results
highlighted,
underscoring
vaccines'
potential
advancing
for
Synergistic
combinatorial
therapies
play
crucial
role,
emphasizing
need
continued
research
collaboration
area.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Окт. 20, 2023
Glioblastoma
is
an
aggressive
primary
brain
tumor
that
has
seen
few
advances
in
treatments
for
over
20
years.
In
response
to
this
desperate
clinical
need,
multiple
immunotherapy
strategies
are
under
development,
including
CAR-T
cells,
immune
checkpoint
inhibitors,
oncolytic
viruses
and
dendritic
cell
vaccines,
although
these
approaches
yet
yield
significant
benefit.
Potential
reasons
the
lack
of
success
so
far
include
immunosuppressive
microenvironment,
blood-brain
barrier,
systemic
changes
system
driven
by
both
its
treatment.
Furthermore,
while
T
cells
essential
effector
control,
play
equally
important
role
activation,
emerging
evidence
suggests
compartment
may
be
deeply
compromised
glioblastoma
patients.
review,
we
describe
currently
development
challenges
faced,
with
a
particular
emphasis
on
critical
cell-T
axis.
We
suggest
number
could
used
boost
function
propose
use
combination
cell-targeting
lead
successful
control.
